Ibex and Alverno Laboratories sign multi-year, multi-tissue expansion agreement of AI for cancer diagnosis

Alverno Laboratories, a provider of high-quality diagnostic testing services and one of the largest integrated laboratory networks in the United States, and Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, today announced a new agreement to expand the deployment of Ibex’s GalenTM suite of Artificial Intelligence (AI) solutions to the entire Alverno network across Illinois and Indiana. The deployment includes AI-powered solutions for cancer diagnosis across multiple tissue types and will support Alverno pathologists in providing the utmost quality of care for their patients.

Under the new expansion agreement, Alverno will make Ibex’s solutions available to all pathologists in its network, which includes more than 30 hospital laboratories and touches over eight million patients’ lives per year across Indiana and Illinois. Building on its earlier investment in digital pathology infrastructure, Alverno is among the first laboratories in the U.S. to digitize its pathology services, harnessing the high-throughput capabilities of the Philips IntelliSite Pathology Solution, and is the first to offer this AI-supported cancer diagnosis in the Midwest region of the United States.

“Alverno will expand the reach of Ibex’s AI technology across our network, providing the most innovative tools to our team of pathologists. With an increasing demand for high-quality cancer testing, Alverno continues to invest in technology to support our growth while remaining focused on high quality patient care,” said Sam Terese, CEO & President of Alverno Laboratories. “Our partnership with Ibex enables Alverno to offer a new level of care to the physicians who treat their patients in our communities, and that is aligned with our mission to continually improve the delivery of quality diagnostic data and laboratory service to our partners and caregivers.”

Ibex’s Galen suite of solutions will support Alverno pathologists in a variety of tasks during routine review of breast, prostate, and gastric biopsies, including case prioritization, AI-powered cancer detection and reporting, and help optimize IHC workflows and drive other productivity-enhancing tools. This implementation of AI on a large scale across the entire laboratory network has the potential to improve pathologists’ productivity and user experience, reduce operational costs and improve overall service levels. Galen is the most widely deployed AI technology in pathology and is used as part of everyday clinical practice at laboratories, hospitals and health systems worldwide. Galen demonstrated outstanding outcomes across multiple clinical studies performed on various tissue types and diagnostic workflows1,2,3,4,5.

“We look forward to our continued collaboration with Alverno, providing its team of expert pathologists with the most advanced AI-powered solutions and supporting diverse patient communities across rural, suburban and large-metro populations,” said Justin McCarthy, Head of U.S. sales at Ibex Medical Analytics. “With over 100,000 new cancer cases expected in the Midwest region in 20236, Ibex is committed to advancing the implementation of AI in pathology to support the growing demand for quality diagnostics.”